Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.3.1.142 - glycoprotein O-fatty-acyltransferase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci.
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Adenocarcinoma of Lung
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Asthma
Lentiviral vector-mediated delivery of lysophosphatidylcholine acyltransferase 1 attenuates airway inflammation in ovalbumin-induced allergic asthmatic mice.
Autoimmune Diseases
p300 protein acetyltransferase activity suppresses systemic lupus erythematosus-like autoimmune disease in mice.
Blindness
Loss of lysophosphatidylcholine acyltransferase 1 leads to photoreceptor degeneration in rd11 mice.
Brain Neoplasms
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Breast Neoplasms
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Carcinogenesis
Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
Carcinoma
Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways.
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Carcinoma, Ductal
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Carcinoma, Hepatocellular
LPCAT1 overexpression promotes the progression of hepatocellular carcinoma.
LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1.
Patt1, a novel protein acetyltransferase that is highly expressed in liver and downregulated in hepatocellular carcinoma, enhances apoptosis of hepatoma cells.
Carcinoma, Intraductal, Noninfiltrating
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Carcinoma, Lobular
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Carcinoma, Squamous Cell
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways.
Colonic Neoplasms
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer.
Diabetes Mellitus, Type 2
A Regulatory Role of LPCAT1 in the Synthesis of Inflammatory Lipids, PAF and LPC, in the Retina of Diabetic Mice.
Diabetic Retinopathy
A Regulatory Role of LPCAT1 in the Synthesis of Inflammatory Lipids, PAF and LPC, in the Retina of Diabetic Mice.
Endometrial Neoplasms
Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer.
Esophageal Neoplasms
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
Leukocyte-Mediated Combined Targeted Chemo and Gene Therapy for Esophageal Cancer.
Esophageal Squamous Cell Carcinoma
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
glycoprotein o-fatty-acyltransferase deficiency
Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Hyperlipidemias
Modulation of Lipid Metabolism by Celastrol.
Infections
Lysophosphatidylcholine acyltransferase 1 is downregulated by hepatitis C virus: impact on production of lipo-viro-particles.
Leber Congenital Amaurosis
Loss of lysophosphatidylcholine acyltransferase 1 leads to photoreceptor degeneration in rd11 mice.
Leukemia
Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Leukemia, Myeloid, Acute
Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Liver Cirrhosis
Chemical profile of Swertia mussotii Franch and its potential targets against liver fibrosis revealed by cross-platform metabolomics.
Lung Neoplasms
Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Lymphatic Metastasis
Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.
Melanoma
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Mouth Neoplasms
Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.
Neoplasm Metastasis
Leukocyte-Mediated Combined Targeted Chemo and Gene Therapy for Esophageal Cancer.
LPCAT1 overexpression promotes the progression of hepatocellular carcinoma.
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways.
LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1.
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.
Neoplasms
A miR-205-LPCAT1 axis contributes to proliferation and progression in multiple cancers.
Diagnostic marker signature for esophageal cancer from transcriptome analysis.
Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas.
Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer.
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia.
Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients.
LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
LPCAT1 Promotes Cutaneous Squamous Cell Carcinoma via EGFR-Mediated Protein Kinase B/p38MAPK Signaling Pathways.
LpCat1 Promotes Malignant Transformation of Hepatocellular Carcinoma Cells by Directly Suppressing STAT1.
LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma.
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancer.
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence.
Lysophosphatidylcholine acyltransferase 1 upregulation and concomitant phospholipid alterations in clear cell renal cell carcinoma.
Membrane Lipid Remodeling Takes Center Stage in Growth Factor Receptor-Driven Cancer Development.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling.
The protein acetyltransferase ARD1: a novel cancer drug target?
Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer.
Neuralgia
Relief from neuropathic pain by blocking of the platelet-activating factor-pain loop.
Pancreatic Neoplasms
Identification of prognostic lipid droplet-associated genes in pancreatic cancer patients via bioinformatics analysis.
Pneumonia
C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia.
Polycystic Ovary Syndrome
Methylome and transcriptome profiling revealed epigenetic silencing of LPCAT1 and PCYT1A associated with lipidome alterations in polycystic ovary syndrome.
Prostatic Neoplasms
Effects of platelet-activating factor and its differential regulation by androgens and steroid hormones in prostate cancers.
Gut Microbiota Dysbiosis Accelerates Prostate Cancer Progression Through Increased LPCAT1 Expression and Enhanced DNA Repair Pathways.
High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers.
LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
Respiratory Distress Syndrome
Gene variants of the phosphatidylcholine synthesis pathway do not contribute to RDS in the Chinese population.
Respiratory Distress Syndrome, Newborn
Genetic Polymorphisms of LPCAT1, CHPT1 and PCYT1B and Risk of Neonatal Respiratory Distress Syndrome among a Chinese Han Population.
Retinal Degeneration
Effects of Subretinal Gene Transfer at Different Time Points in a Mouse Model of Retinal Degeneration.
Molecular screening of the LPCAT1 gene in patients with retinitis pigmentosa without defined mutations in known retinitis pigmentosa genes.
Retinal Diseases
Temporal ChIP-on-Chip of RNA-Polymerase-II to detect novel gene activation events during photoreceptor maturation.
Retinitis Pigmentosa
Loss of lysophosphatidylcholine acyltransferase 1 leads to photoreceptor degeneration in rd11 mice.
Molecular screening of the LPCAT1 gene in patients with retinitis pigmentosa without defined mutations in known retinitis pigmentosa genes.
Sepsis
LPS impairs phospholipid synthesis by triggering beta-transducin repeat-containing protein (beta-TrCP)-mediated polyubiquitination and degradation of the surfactant enzyme acyl-CoA:lysophosphatidylcholine acyltransferase I (LPCAT1).
Tuberculosis
Acetylation of acetyl-CoA synthetase from Mycobacterium tuberculosis leads to specific inactivation of the adenylation reaction.
Characterization of protein acyltransferase function of recombinant purified GlnA1 from Mycobacterium tuberculosis: A moon lighting property.
Novel protein acetyltransferase, Rv2170, modulates carbon and energy metabolism in Mycobacterium tuberculosis.